BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform
BNB Plus Corp. (BNBX)
Company Research
Source: Business Wire
Patent Covers the Composition of LineaRx's Proprietary Linea™ RNA Polymerase (RNAP), a Core Technology Empowering the Linea™ IVT Platform NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis."The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP. The Company plans to validate the patent in key European markets to provide patent protection through at least 2040."Securing patent protection in Europe is a significant milestone in building our global intellectual property portfolio around Linea IVT," said Clay Shorrock, CEO of BNBX. "Together with our U.S. patent, this Eu
Show less
Read more
Impact Snapshot
Event Time:
BNBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNBX alerts
High impacting BNB Plus Corp. news events
Weekly update
A roundup of the hottest topics
BNBX
News
- BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine DevelopersBusiness Wire
- BNB Plus: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board DirectorBusiness Wire
- Applied Dna Sciences (NASDAQ:BNBX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e+)" rating on the stock.MarketBeat
- BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27thBusiness Wire
BNBX
Sec Filings
- 3/24/26 - Form SCHEDULE
- 3/24/26 - Form DEF
- 3/24/26 - Form 8-K
- BNBX's page on the SEC website